How India Exports Vinorelbine to the World

Vinorelbine received FDA approval in December 1994 for the treatment of non-small cell lung cancer. The original brand, Navelbine, manufactured by Pierre Fabre, was approved in an injectable formulation. However, all formulations of Navelbine have since been discontinued. As of February 12, 2026, there are no active generic versions of Navelbine available in the U.S. market.

The absence of active Abbreviated New Drug Applications (ANDAs) for vinorelbine in the U.S. suggests limited competition, potentially impacting market dynamics. Given that 78 Indian exporters are actively involved in vinorelbine exports, there exists an opportunity for these manufacturers to explore the U.S. market, provided they navigate the FDA's regulatory pathways effectively.

In the European Union, vinorelbine is approved for the treatment of non-small cell lung cancer and metastatic breast cancer. The European Medicines Agency (EMA) has conducted periodic safety update report single assessments (PSUSAs) for vinorelbine, with the most recent procedure (PSUSA/00003124/202204) resulting in a variation to the marketing authorization as of January 24, 2023. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) guidelines for marketing authorization holders. Indian exporters targeting these markets must ensure adherence to EU GMP standards to facilitate market entry.

Vinorelbine is listed on the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The 24th edition of the list, published in September 2025, includes vinorelbine, reflecting its essential status. (who.int)

Inclusion in the WHO Model List facilitates its adoption in national essential medicines lists, potentially increasing demand in various countries. Manufacturers must ensure compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to meet quality requirements across different markets.

In India, vinorelbine is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription drug requiring medical supervision. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, vinorelbine is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. Exporters must ensure compliance with these requirements to facilitate smooth international trade.

The primary patents for vinorelbine have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, including Indian exporters, who now have the opportunity to capture market share by offering cost-effective alternatives.

In May 2025, the WHO's 25th Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming vinorelbine's inclusion and highlighting its continued relevance in cancer treatment. (who.int)

In January 2023, the EMA concluded a PSUSA for vinorelbine, resulting in variations to the product information to enhance safety and efficacy profiles. (ema.europa.eu)

In July 2023, the WHO published the 9th edition of the Model List of Essential Medicines for Children, emphasizing the importance of essential medicines in pediatric care. (who.int)

In September 2025, the WHO released the 24th edition of the Model List of Essential Medicines, which includes vinorelbine, underscoring its essential status in global health. (who.int)

In December 2018, the EMA granted orphan designation to vinorelbine tartrate for the treatment of soft tissue sarcoma, recognizing its potential in addressing rare cancers. (ema.europa.eu)

These developments reflect the dynamic regulatory environment surrounding vinorelbine, necessitating continuous monitoring by stakeholders to ensure compliance and capitalize on emerging opportunities.

Vinorelbine, a chemotherapy agent, is primarily produced in India and China. According to the U.S. Pharmacopeia, 58% of Key Starting Materials (KSMs) for U.S.-approved Active Pharmaceutical Ingredients (APIs) are sourced from a single country, with 41% from China and 16% from India. This heavy reliance on these nations for KSMs introduces significant supply chain vulnerabilities.

Recent geopolitical tensions have exacerbated these risks. In March 2026, the closure of the Strait of Hormuz disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Such disruptions can have cascading effects on the availability of APIs like Vinorelbine, highlighting the fragility of current sourcing strategies.

Our proprietary trade data indicates that the top five Indian exporters of Vinorelbine account for 81.4% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 37.1%. This high concentration poses a significant single-source risk. While India's Production Linked Incentive (PLI) scheme aims to bolster domestic API production and reduce import dependence, its full impact on diversifying Vinorelbine suppliers remains to be seen.

The recent conflict in the Middle East has led to the effective shutdown of the Strait of Hormuz, a critical maritime chokepoint. This disruption has halted naphtha shipments, a key feedstock for chemical production, affecting Asian chemical manufacturers. Additionally, the conflict has disrupted air routes, posing risks to the supply of critical medicines, including cancer drugs, to the Gulf region. Such geopolitical events underscore the vulnerability of pharmaceutical supply chains to regional instabilities.

• Diversify Supplier Base: Engage with multiple Vinorelbine suppliers across different regions to reduce dependency on a limited number of exporters.

• Strengthen Domestic Production: Leverage India's PLI scheme to encourage the establishment of additional domestic manufacturing units for Vinorelbine and its KSMs.

• Enhance Supply Chain Visibility: Implement robust tracking systems to monitor the sourcing and movement of raw materials and finished products, enabling proactive risk management.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical disruptions on supply chains.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA and EMA to stay informed about potential shortages and regulatory changes affecting Vinorelbine supply.

RISK_LEVEL: HIGH